Investigational Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis

Expert Opinion on Investigational Drugs

Volumn 25, Issue 8, 2016, Pages 891-899

  Norman, Peter ^a  

^a Norman Consulting   (United Kingdom)

Author keywords

Autoimmune disease; B cell; Btk kinase; ibrutinib; rheumatoid arthritis; spebrutinib

Indexed keywords

ACALABRUTINIB; BRUTON TYROSINE KINASE INHIBITOR; CYSTEINE; IBRUTINIB; M 2951; OLMUTINIB; PRN 1008; SPEBRUTINIB; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; NEW DRUG; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TEC PROTEIN-TYROSINE KINASE;

AUTOIMMUNE DISEASE; DRUG EFFICACY; DRUG MANUFACTURE; HUMAN; NONHUMAN; ONCOLOGY; PRECLINICAL STUDY; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DRUG DESIGN; DRUG RESISTANCE; PATHOPHYSIOLOGY;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DRUG DESIGN; DRUG RESISTANCE; DRUGS, INVESTIGATIONAL; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84978472374     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2016.1182499     Document Type: Review

References (54)

1. D.J.Rawlings, O.N.Witte The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function. Semin Immunol. 1995 Aug;7(4):237–246.• The structural biology of the Tec family.
2. H.Mano. The Tec family protein-tyrosine kinases: a subset of kinases for a subset of signalings. Int J Hematol. 1999 Jan;69(1):6–12.• The signaling role of Tec kinases.
3. J.A.Readinger, K.L.Mueller, A.M.Venegas, et al. Tec kinases regulate T-lymphocyte development and function: new insights into the roles of ITK and RLK/TXK. Immunol Rev. 2009 Mar;228(1):93–114.
4. J.A.Readinger, K.L.Mueller, A.M.Venegas, et al. Structures of human Bruton’s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Immunol Rev. 2009;228(1):93–114.•• Key structural biology paper on BTK kinase.
5. A.Aalipour, R.H.Advani. Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Ther Adv Hematol. 2014 Aug;5(4):121–133.
6. J.M.Drake, J.K.Lee, O.N.Witte. Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer. Mol Cell Biol. 2014 May;34(10):1722–1732.
7. A.Hussain, L.Yu, R.Faryal, et al. TEC family kinases in health and disease–loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK. Febs J. 2011 Jun;278(12):2001–2010.
8. N.Kutsch, R.Marks, R.Ratei, et al. Role of tyrosine kinase inhibitors in indolent and other mature B-cell neoplasms. Biomark Insights. 2015 Aug 16;10(Suppl3):15–23.
9. K.D.Puri, J.A.Di Paolo, M.R.Gold. B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies. Int Rev Immunol. 2013 Aug;32(4):397–427.
10. J.A.Whang, B.Y.Chang. Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Drug Discov Today. 2014 Aug;19(8):1200–1204.• Earlier review on BTK inhibitors and rheumatoid arthritis.
11. V.C.Kyttaris, G.C.Tsokos. Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus. Curr Opin Rheumatol. 2011 Sep;23(5):449–453.
12. J.S.Chen, L.C.Chang, S.J.Huang, et al. Targeting spleen tyrosine kinase-Bruton’s tyrosine kinase axis for immunologically mediated glomerulonephritis. Biomed Res Int. 2014;2014:814869.
13. M.Nakou, G.Katsikas, P.Sidiropoulos, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11(4):R131.
14. E.K.Evans, R.Tester, S.Aslanian, et al. Inhibition of BTK with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013;346(2):219–228.•• Detailed studies with spebrutinib.
15. Q.Shi, A.Tebben, A.J.Dyckman, et al. Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases. Bioorg Med Chem Lett. 2014 May 1;24(9):2206–2211.
16. J.Liu, D.Guiadeen, A.Krikorian, et al. Discovery of 8-amino-imidazo[1,5-a]pyrazines as reversible BTK inhibitors for the treatment of rheumatoid arthritis. ACS Med Chem Lett. 2016;7(2):198–203. doi:10.1021/acsmedchemlett.5b00463.•• The most selective BTK inhibitor described to date.
17. C.R.Smith, D.R.Dougan, M.Komandla, et al. Fragment-based discovery of a small molecule inhibitor of Bruton’s Tyrosine Kinase. J Med Chem 2015 Jul23;58(14):5437–5444.• Distinct approach to the identification of BTK inhibitors.
18. D.Xu, Y.Kim, J.Postelnek, et al. RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J Pharmacol Exp Ther. 2012;341(1):90–103.
19. W.B.Young, J.Barbosa, P.Blomgren, et al. Discovery of highly potent and selective Bruton’s tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability. Bioorg Med Chem Lett. 2016 Jan 15;26(2):575–579.
20. J.C.Byrd, B.Harrington, S.O’Brien, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–332.
21. T.Covey, T.Barf, M.Gulrajani, et al. ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Res. 2015;75(15Suppl):Abstractnr 2596.
22. H.Parmar, Immunology from symptom relief to disease modification, Merck Serono Investor and Analyst Day [cited 2014 Sep 18]. Available from: http://www.merck.de/company.merck.de/de/images/6_Presentation_Immunology_tcm1613_128736.pdf?Version=.
23. J.K.Park, J.A.Park, Y.J.Lee, et al. THU0499 Hm71224, a novel oral BTK inhibitor, inhibits human immune cell activation: new drug candidate to treat B-cell associated autoimmune diseases. Ann Rheum Dis. 2014;73:355–356.
24. S.Y.Yang, Y.Y.Kim, J.Y.Song, et al. HM71224, A novel Btk inhibitor demonstrates potent activities in rodent models of arthritis. Ann Rheum Dis. 2014;73(Suppl2):518–519.
25. Y.Y.Kim, K.T.Park, K.H.Lee, et al. FRI0380 HM71224, A selective Bruton’s Tyrosine Kinase inhibitor, ameliorates murine lupus development. Ann Rheum Dis. 2015;74:564.
26. J.Lee, J.Son, H.J.Sin, et al. THU0185 Safety, pharmacokinetics and proof-of-mechanism of an oral Bruton’s Tyrosine Kinase inhibitor HM71224 in healthy adult volunteers. Ann Rheum Dis. 2015;74:261.
27. J.M.Bradshaw, J.M.McFarland, V.O.Paavilainen, et al. Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nat Chem Biol. 2015;11(7):525–531.• Understanding the requirements with covalent kinase inhibitors.
28. R.J.Hill, P.Smith, J.Krishnarajah, et al. Discovery of PRN1008, a novel, reversible covalent BTK inhibitor in clinical development for rheumatoid arthritis [abstract]. Arthritis Rheumatol. 2015;67((suppl):10.
29. P.F.Smith, J.Krishnarajah, P.A.Nunn, et al. SAT0232 A phase 1 clinical trial of PRN1008, an oral, reversible, covalent BTK inhibitor demonstrates clinical safety and therapeutic levels of BTK occupancy without sustained systemic exposure. Ann Rheum Dis. 2015;74:742.
30. L.Madakamutil. Discovery of a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for autoimmune diseases. 3rd International Conference and Exhibition on Clinical & Cellular Immunology (Immunology Summit-2014); Sep 29–Oct1 2014; Baltimore, MD. (see http://www.omicsgroup.com/conferences/ACS/conference/pdfs/12834-Speaker-Pdf-T.pdf)
31. G.Hirst, Fragment based drug discovery. Sweating the small stuff is worth it. 5th RSC-BMCS Fragment-Based Drug Discovery Meeting; March 22nd – 24th 2015; Cambridge, UK. (see http://www.maggichurchouseevents.co.uk/bmcs/Downloads/Fragments%20-%20Tue%201415%20Hirst%20Gavin.pdf)
32. T.Yoshizawa, Y.Ariza, Y.Ueda, et al. Development of a Bruton’s Tyrosine Kinase (Btk) inhibitor, ONO-4059: Efficacy in a Collagen Induced Arthritis (CIA) model indicates potential treatment for Rheumatoid Arthritis (RA). Arthritis Rheum. 2012;64(Suppl 10):1660.
33. Y.Ariza, T.Yoshizawa, Y.Ueda, et al. ONO-4059 – A novel small molecule dual inhibitor of Bruton’s Tyrosine Kinase (Btk) and Tec kinase- suppresses osteoclastic bone resorption and inflammation. Arthritis Rheum. 2013;65(Suppl 10):1824.
34. C.Goess, C.Graff, T.T.Zhang, et al. Efficacy of abbv-105, a selective and irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK), in multiple models of inflammation. Arthritis Rheumatol. 2015;67(suppl 10).
35. F.Hosoi, S.Iguchi, Y.Yoshiga, et al. OP0075 TAS5315, A novel Bruton’s Tyrosine Kinase (BTK) inhibitor, demonstrates potent efficacy in mouse Collagen-Induced Arthritis Model. Ann Rheum Dis. 2015;74(Suppl2):97.
36. S.Morris, A.Laurent, L.Jerome, et al. Pre-clinical development of a novel, potent and selective BTK inhibitor for autoimmune disease and inflammation including arthritis. Arthritis Rheumatol. 2015;67(suppl 10).
37. S.Chalmers, J.Doerner, T.Bosanac, et al. Blockade of immune complex-mediated glomerulonephritis by highly selective inhibition of Bruton’s Tyrosine Kinase. Arthritis Rheumatol. 2015;67(suppl 10).
38. See Hardman & Co, RedX pharma, [2016 Jan21]. Available from: http://www.hardmanandco.com/system/files/research_papers/Redx Pharma.pdf.• The most comprehensive data on RedX’ BTK program.
39. V.Walker, N.E.S.Guisot, S.Best, et al. Development of REDX05194, a novel, potent and selective inhibitor of Bruton’s Tyrosine Kinase (BTK) as a potential treatment for B-cell malignancies. Blood. 2015;126(23):4848.
40. Hoffman La Roche Inc, Ono Pharmaceutical Co., Combination therapy of an anti CD20 antibody with A BTK inhibitor. WO2015067586. 2015.
41. L.A.Honigberg, A.M.Smith, M.Sirisawad, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075–13080.
42. M.Shinohara, B.Y.Chang, J.J.Buggy, et al. The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss. Bone. 2014;60:8–15.
43. W.B.Young, J.Barbosa, P.Blomgren, et al. Potent and selective Bruton’s tyrosine kinase inhibitors: discovery of GDC-0834. Bioorg Med Chem Lett. 2015 Mar 15;25(6):1333–1337.
44. L.Liu, J.Di Paolo, J.Barbosa, et al. Antiarthritis effect of a novel Bruton’s tyrosine kinase (BTK) inhibitor in rat CIA and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol Exp Ther. 2011;338(1):154–163.•• The most detailed animal studies with a BTK inhibitor in the CIA model.
45. L.Liu, J.S.Halladay, Y.Shin, et al. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton’s tyrosine kinase inhibitor. Drug Metab Dispos. 2011;39(10):1840–1849.
46. J.K.Sodhi, S.Wong, D.S.Kirkpatrick, et al. A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834. Drug Metab Dispos. 2015 Jun;43(6):908–915.
47. Y.Lou, X.Han, A.Kuglstatter, et al. Structure-based drug design of RN486, a potent and selective Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis. J Med Chem 2015 Jan8;58(1):512–516.• Detailed structural approach to BTK inhibitor design.
48. P.Mina-Osorio, J.Lastant, N.Keirstead, et al. Suppression of glomerulonephritis in lupus prone NZB/W mice by RN486, a selective inhibitor of Bruton’s Tyrosine Kinase. Arthritis Rheum. 2013 Sep;65(9):2380–2391.
49. Y.Lou, Z.K.Sweeney, A.Kuglstatter, et al. Finding the perfect spot for fluorine: improving potency up to 40-fold during a rational fluorine scan of a Bruton’s Tyrosine Kinase (BTK) inhibitor scaffold. Bioorg Med Chem Lett. 2015 Jan 15;25(2):367–371.
50. J.A.Di Paolo, T.Huang, M.Balazs, et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol. 2011;7(1):41–50.
51. S.Cohen, R.Fleischmann. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol. 2010 May;22(3):330–335.
52. V.C.Kyttaris. Kinase inhibitors: a new class of antirheumatic drugs. Drug Des Devel Ther. 2012;6:245–250.
53. D.Chiron, M.Di Liberto, P.Martin, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014;4:1022–1035.
54. S.B.Cohen, -T.-T.Cheng, V.Chindalore, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 2009;60(2):335–344.